Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) Sees Large Decline in Short Interest

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 13,200 shares, a drop of 24.6% from the November 30th total of 17,500 shares. Based on an average trading volume of 27,200 shares, the short-interest ratio is currently 0.5 days.

Reviva Pharmaceuticals Stock Performance

NASDAQ RVPHW traded down $0.03 during trading on Friday, hitting $0.18. 20,319 shares of the company’s stock traded hands, compared to its average volume of 20,192. The stock has a fifty day moving average of $0.19 and a two-hundred day moving average of $0.18. Reviva Pharmaceuticals has a 12-month low of $0.07 and a 12-month high of $1.62.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.